COVID-19 pharma news hub2020-09-15T10:24:39+01:00

COVID-19 pharma news hub

Our COVID-19 hub collates our thoughts on the key considerations and strategies for pharma companies, highlighting emerging patterns in the pharma industry and crucially how these may shape the market in the future.

Please note: COVID-19’s impact on pharma is continually evolving. All insights expressed here are dated individually and were formulated based on the situation at that time.

live webinar

Episode 2: Leading in a crisis: Driving value for your customers, your organization, and yourself

Thursday, October 8, 2020 11:00 EST

Join Peter Hempshall, Deallus CEO, and Rita Numerof, President of Numerof & Associates for Episode 2 of their discussion series – Leading in a crisis. This episode will explore topics around how leaders can manage effectively during a crisis and continue to deliver value for their customers, their organizations, and for themselves. Any business leader eager to explore tactics, best practices, and learning experiences gained from leading in times of uncertainty will find value in this episode.

Article

COVID-19 – tracking the fast-moving landscape

Top 12 COVID-19 treatments

As COVID-19 continues to impact patients, healthcare systems, and global economic outlooks, we focus on the key considerations and strategies for pharma companies when the data generation for possible therapies is becoming increasingly complex to analyze. There are several COVID-19 treatment and vaccine databases containing an aggregation of publicly-available information from validated sources detailing treatments and vaccines currently in development… [more]

Read more

Remdesivir’s journey

The COVID-19 pandemic will shape several future market trends within the pharmaceutical industry – trends that we need to understand the impact of today so we can successfully navigate them in the future.

In terms of emerging macro trends, one notable impact of COVID-19 has been on the stock market within the healthcare sector, historically considered a safe haven for investors during financial crises. We look at Remdesivir’s journey and its impact on share price… [more]

see full story

COVID-19 related news and thought leadership

Episode 2: Leading in a crisis

Categories: News|Tags: , |

Join Peter Hempshall, Deallus CEO, and Rita Numerof, President of Numerof & Associates for Episode 2 of their discussion series - Leading in a crisis. This episode will explore topics around how leaders can manage effectively during a crisis and continue to deliver value for their customers, their organizations, and for themselves. Any business leader eager to explore tactics, best practices, and learning experiences gained from leading in times of uncertainty will find value in this episode.

Remdesivir’s journey and its impact on share price

Categories: News, Thought Piece|Tags: , , |

The COVID-19 pandemic will shape several future market trends within the pharmaceutical industry. In terms of emerging macro trends, one notable impact of COVID-19 has been on the stock market within the healthcare sector, historically considered a safe haven for investors during financial crises. Our infographic plots significant events in Remdesivir’s recent history to contextualize this dramatic story and the seemingly disproportionate impact one product’s journey appeared to have on the overall company stock price.

OnDemand Webinar – Navigating Market Disruption after COVID-19

Categories: News, Thought Piece, Video|Tags: , |

Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussions on ‘Navigating Market Disruption After Covid-19’. This OnDemand webinar discusses how the pandemic has accelerated market shifts already in play, disrupting current business models, and dramatically altering how pharma business will be done in the future.

COVID-19 – tracking the fast-moving landscape

Categories: Thought Piece|Tags: , |

As the COVID-19 pandemic continues to impact patients, healthcare systems, and global economic outlooks, we focus on the key considerations and strategies for pharma companies when the data generation for possible therapies is becoming increasingly complex to analyze. There are several COVID-19 treatment and vaccine databases containing an aggregation of publicly-available information from validated sources detailing treatments and vaccines currently in development.

COVID-19, China, and Telemedicine

Categories: Thought Piece|Tags: , |

As COVID-19 continues to disrupt normalcy across the globe, China is responding with innovation in online health delivery and telemedicine. How has China encouraged telemedicine uptake? What are the factors contributing to China’s relatively quick utilization of telemedicine in the face of COVID-19? And what learnings can we gain from taking a closer look? We explore these questions in our latest addition to our COVID-19+Pharma Series.

Launch and COVID-19: Pharma’s Dilemma

Categories: Thought Piece|Tags: , |

COVID-19 is throwing a wrench in years’ worth of launch planning, introducing complications and delays into the regulatory process and severely constricting promotional and educational opportunities for new products. How is the pharmaceutical industry responding to these changes in well-laid plans? How are regulatory bodies responding? We consider the potential impact of the pandemic on launch timing and strategy here.

Get in touch with us

We’re ready and waiting to talk about how we can assist you.

Over the coming months, we will highlight the emerging patterns in the pharma industry caused by COVID-19 and crucially how this may shape the market in the future. Stay tuned for further insights.

Go to Top